[Clinical studies on cefpimizole in the field of obstetrics and gynecology].
Cefpimizole (AC-1370), a new cephem antibiotic, was studied clinically in the field of obstetrics and gynecology, and the following results were obtained. AC-1370 was administered to 7 patients with gyneco-obstetrical infections, and the therapeutic efficacy was 85.7% (6 cases of 7 cases). E. coli was isolated as causative pathogen in 4 cases out of 7 cases, and was eliminated in all cases after the AC-1370 treatment. S. faecalis was eliminated in 2 cases out of 3 cases, and B. fragilis was eliminated in all 3 cases. As abnormal laboratory findings, transient elevation of GOT, GPT and A1-P was observed in 1 case but became normal after cessation of AC-1370 administration. The therapeutic effect was poor for this case.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002511:Cephalosporins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004926:Escherichia coli / Q000302:isolation & purification; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged
D002511:Cephalosporins; C038845:cefpimizole